{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:53:17Z","timestamp":1769021597810,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2012,9,18]],"date-time":"2012-09-18T00:00:00Z","timestamp":1347926400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Health Econ"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1007\/s10198-012-0432-5","type":"journal-article","created":{"date-parts":[[2012,9,17]],"date-time":"2012-09-17T03:45:18Z","timestamp":1347853518000},"page":"875-885","source":"Crossref","is-referenced-by-count":20,"title":["Patients\u2019 access to biologics in rheumatoid arthritis: a comparison between Portugal and other European countries"],"prefix":"10.1007","volume":"14","author":[{"given":"P. A.","family":"Laires","sequence":"first","affiliation":[]},{"given":"F.","family":"Exposto","sequence":"additional","affiliation":[]},{"given":"R.","family":"Mesquita","sequence":"additional","affiliation":[]},{"given":"A. P.","family":"Martins","sequence":"additional","affiliation":[]},{"given":"L.","family":"Cunha-Miranda","sequence":"additional","affiliation":[]},{"given":"J. E.","family":"Fonseca","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2012,9,18]]},"reference":[{"issue":"42","key":"432_CR1","first-page":"3","volume":"10","author":"YF Chen","year":"2006","unstructured":"Chen, Y.F., Jobanputra, P., Barton, P., et al.: A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol. Assess. 10(42), 3\u20134 (2006)","journal-title":"Health Technol. Assess."},{"key":"432_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00019053-200422001-00002","volume":"22","author":"TK Kvien","year":"2004","unstructured":"Kvien, T.K.: Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 22, 1\u201312 (2004)","journal-title":"Pharmacoeconomics"},{"key":"432_CR3","unstructured":"Matos, A.A., Branco, J.C., Canas Silva, J., Viana Queiroz, M., P\u00e1dua, F.: Inqu\u00e9rito epidemiol\u00f3gico de doen\u00e7as reum\u00e1ticas numa amostra da popula\u00e7\u00e3o portuguesa (resultados preliminares). Acta Reumatol. Port. 16(1), 98 (1991)"},{"key":"432_CR4","volume-title":"Rheumatoid arthritis\u2014National clinical guideline for management and treatment in adults","author":"National Institute for Health and Clinical Excellence","year":"2009","unstructured":"National Institute for Health and Clinical Excellence: Rheumatoid arthritis\u2014National clinical guideline for management and treatment in adults. NICE, London (2009)"},{"key":"432_CR5","doi-asserted-by":"crossref","unstructured":"Singh, J.A., Christensen, R., Wells, G.A., et al.: Biologics for rheumatoid arthritis: an overview of Cochrane reviews (Review). Cochrane Database Syst. Rev. (4) (2009). doi: 10.1002\/14651858.CD007848.pub2","DOI":"10.1002\/14651858.CD007848.pub2"},{"issue":"6","key":"432_CR6","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1136\/ard.2009.126532","volume":"69","author":"JS Smolen","year":"2010","unstructured":"Smolen, J.S., Landew\u00e9, R., Breedveld, F.C., et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann. Rheum. Dis. 69(6), 964\u2013975 (2010). doi: 10.1136\/ard.2009.126532","journal-title":"Ann. Rheum. Dis."},{"key":"432_CR7","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s10198-007-0089-7","volume":"8","author":"B J\u00f6nsson","year":"2008","unstructured":"J\u00f6nsson, B., Kobelt, G., Smolen, J.: The burden of rheumatoid arthritis and access to treatment: uptake of new therapies. Eur. J. Health Econ. 8, 61\u201386 (2008). doi: 10.1007\/s10198-007-0089-7","journal-title":"Eur. J. Health Econ."},{"key":"432_CR8","unstructured":"Kobelt, G., Kasteng, F.: Access to innovative treatments in rheumatoid arthritis in Europe. A report prepared for the European Federation of Pharmaceutical Industry Associations (EFPIA). http:\/\/www.lif.se\/default.aspx?id=44400 (2009). Accessed December 2011"},{"key":"432_CR9","unstructured":"Miltenburger, C., Gunther, O., Justo, N., et al.: A survey of barriers to treatment access in rheumatoid arthritis in France, Germany, Italy, Spain and the UK (2009). Accessed December 2011"},{"issue":"4","key":"432_CR10","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1136\/ard.2008.100362","volume":"68","author":"P Emery","year":"2009","unstructured":"Emery, P., Van Vollenhoven, R., Ostergaard, M., et al.: Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe. Ann. Rheum. Dis. 68(4), 456\u2013459 (2009). doi: 10.1136\/ard.2008.100362","journal-title":"Ann. Rheum. Dis."},{"key":"432_CR11","first-page":"2","volume":"2","author":"M Cruz","year":"2002","unstructured":"Cruz, M., Fonseca, J.E., Branco, J.C.: Artrite reumat\u00f3ide: paradigma das doen\u00e7as reum\u00e1ticas cr\u00f3nicas. Tecnologia M\u00e9dica 2, 2\u201311 (2002)","journal-title":"Tecnologia M\u00e9dica"},{"key":"432_CR12","first-page":"21","volume":"29","author":"M Cruz","year":"2004","unstructured":"Cruz, M., Fonseca, J.E., Branco, J.C.: Tr\u00eas anos de administra\u00e7\u00e3o de etanercept e infliximab a doentes com artrite reumat\u00f3ide refract\u00e1ria\u2014avalia\u00e7\u00e3o cl\u00ednica e radiogr\u00e1fica e seguran\u00e7a. Acta Reumatol. Port. 29, 21\u201332 (2004)","journal-title":"Acta Reumatol. Port."},{"key":"432_CR13","first-page":"161","volume":"29","author":"A Barcelos","year":"2004","unstructured":"Barcelos, A., Salvador, M.J., da Silva, J.A., et al.: Indu\u00e7\u00e3o de auto anticorpos durante tratamento prolongado com infliximab em doentes com artrite reumat\u00f3ide. Acta Reumatol. Port. 29, 161\u2013167 (2004)","journal-title":"Acta Reumatol. Port."},{"key":"432_CR14","first-page":"63","volume":"30","author":"Grupo de Estudos de Artrite Reumat\u00f3ide da Sociedade Portuguesa de Reumatologia","year":"2005","unstructured":"Grupo de Estudos de Artrite Reumat\u00f3ide da Sociedade Portuguesa de Reumatologia: An\u00e1lise de 376 doentes com Artrite Reumat\u00f3ide submetidos a terap\u00eautica biol\u00f3gica registados na base de dados de agentes biol\u00f3gicos da Sociedade Portuguesa de Reumatologia. Acta Reumatol. Port. 30, 63\u201371 (2005)","journal-title":"Acta Reumatol. Port."},{"issue":"1","key":"432_CR15","first-page":"45","volume":"36","author":"H Canh\u00e3o","year":"2011","unstructured":"Canh\u00e3o, H., Faustino, A., Martins, F., et al.: Reuma.pt\u2014the rheumatic diseases portuguese register. Acta Reumatol. Port. 36(1), 45\u201356 (2011)","journal-title":"Acta Reumatol. Port."},{"key":"432_CR16","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology: WHODD guidelines for ATC classification and DDD assignment 2010. Norwegian Institute of Public Health. http:\/\/www.whocc.no\/atc_ddd_index (2010). Accessed January 2011"},{"key":"432_CR17","unstructured":"United Nations Development Programme: Human Development Report 2007\/2008. http:\/\/hdrstats.undp.org\/en\/indicators\/default.html (2007)"},{"key":"432_CR18","unstructured":"United Nations Development Programme: Human Development Report 2010. http:\/\/hdr.undp.org\/en\/reports\/global\/hdr2010\/chapters\/ (2010)"},{"key":"432_CR19","unstructured":"Eurostat database Directorate-General (DG) of the European Commission. http:\/\/epp.eurostat.ec.europa.eu (1953)"},{"key":"432_CR20","unstructured":"World Economic Outlook Database, April 2011. International Monetary Fund. http:\/\/www.imf.org\/external\/pubs\/ft\/weo\/2011\/01\/weodata\/weoselgr.aspx (2011). Accessed April 2011"},{"key":"432_CR21","unstructured":"Observat\u00f3rio Do Medicamento e Produtos de Sa\u00fade: Consumo de Medicamentos em meio hospitalar. In. INFARMED (2010)"},{"key":"432_CR22","unstructured":"MIDAS Database. IMS Health. Accessed January 2011"},{"issue":"4","key":"432_CR23","doi-asserted-by":"crossref","first-page":"SR1","DOI":"10.12659\/MSM.881697","volume":"17","author":"E Orlewska","year":"2011","unstructured":"Orlewska, E., Ancuta, I., Anic, B., et al.: Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countries. Med. Sci. Monit. 17(4), SR1\u2013SR13 (2011)","journal-title":"Med. Sci. Monit."},{"key":"432_CR24","author":"PJ Rousseeuw","year":"1987","unstructured":"Rousseeuw, P.J.: Silhouettes: a graphical aid to the interpretation and validation of cluster analysis. Computational and applied mathematics. J. Comput. Appl. Math. (1987). doi: 10.1016\/0377-0427(87)90125-7","journal-title":"J. Comput. Appl. Math."},{"key":"432_CR25","unstructured":"Associa\u00e7\u00e3o Nacional dos Doentes com Artrite Reumat\u00f3ide: Impacto dos medicamentos biol\u00f3gicos na qualidade de vida dos doentes. Paper presented at the Plataforma Mais Sa\u00fade, INFARMED, Portugal, 22 Nov 2011"},{"key":"432_CR26","unstructured":"Cunha-Miranda, L., Santos, H., Ferreira, J., et al.: Finding Rheumatoid Arthritis Impact on Life (FRAIL Study): economic burden. Acta Reumatol. Port. (37), 134\u2013142 (2012)"},{"issue":"3","key":"432_CR27","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s10198-010-0246-2","volume":"11","author":"L Gul\u00e1csi","year":"2010","unstructured":"Gul\u00e1csi, L.: Future challenges for health economics and health technology assessment of biological drugs. Eur. J. Health Econ. 11(3), 235\u2013238 (2010). doi: 10.1007\/s10198-010-0246-2","journal-title":"Eur. J. Health Econ."},{"issue":"3","key":"432_CR28","first-page":"384","volume":"35","author":"S Ramiro","year":"2010","unstructured":"Ramiro, S., Canh\u00e3o, H., Branco, J.C.: EpiReumaPt protocol\u2014Portuguese epidemiologic study of the rheumatic diseases. Acta Reumatol. Port. 35(3), 384\u2013390 (2010)","journal-title":"Acta Reumatol. Port."},{"key":"432_CR29","doi-asserted-by":"crossref","unstructured":"Drosos, A.A., Lanchbury, J.S., Panayi, G.S., et al.: Rheumatoid arthritis in greek and british patients. A comparative clinical, radiologic, and serologic study. Arthritis Rheum. 35(7), 745\u2013748 (1992). doi: 10.1002\/art.1780350705","DOI":"10.1002\/art.1780350705"},{"key":"432_CR30","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/rheumatology\/37.2.165","volume":"37","author":"C Salvarani","year":"1998","unstructured":"Salvarani, C., Macchioni, P.L., Mantovani, W., et al.: HLA-DRB1 alleles associated with rheumatoid arthritis in northern Italy: correlation with disease severity. Br. J. Rheumatol. 37, 165\u2013169 (1998)","journal-title":"Br. J. Rheumatol."},{"issue":"1","key":"432_CR31","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/art.1780370125","volume":"37","author":"E Ronda","year":"1994","unstructured":"Ronda, E., Ruiz, M.T., Pascual, E., et al.: Differences between Spanish and British patients in the severity of rheumatoid arthritis: comment on the article by Drosos et al. Arthritis Rheum. 37(1), 147\u2013148 (1994). doi: 10.1002\/art.1780370125","journal-title":"Arthritis Rheum."},{"key":"432_CR32","first-page":"607","volume":"22","author":"JF Benazet","year":"1995","unstructured":"Benazet, J.F., Reviron, D., Mercier, D., et al.: HLADRB1 alleles associated with rheumatoid arthritis in southern France: absence of extraarticular disease despite expression of the shared epitope. J. Rheumatol. 22, 607\u2013610 (1995)","journal-title":"J. Rheumatol."}],"container-title":["The European Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-012-0432-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10198-012-0432-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-012-0432-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T07:02:57Z","timestamp":1559113377000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10198-012-0432-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,18]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["432"],"URL":"https:\/\/doi.org\/10.1007\/s10198-012-0432-5","relation":{},"ISSN":["1618-7598","1618-7601"],"issn-type":[{"value":"1618-7598","type":"print"},{"value":"1618-7601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,18]]}}}